Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Background: Ayahuasca is a traditional Amazon brew and its potential antidepressant properties have recently been explored in scientific settings. We conducted a double-blind placebo-controlled trial of ayahuasca with treatment-resistant depression patients ( n = 28) and healthy controls ( n = 45). Aims: We are evaluating the blood inflammatory biomarkers: C-reactive protein and interleukin 6, as a potential consequence of ayahuasca intake and their correlation with serum cortisol and brain-derived neurotrophic factor levels. Blood samples were collected at pre-treatment and 48 hours after substance ingestion to assess the concentration of inflammatory biomarkers, together with administration of the Montgomery-Åsberg Depression Rating Scale. Results: At pre-treatment, patients showed higher C-reactive protein levels than healthy controls and a significant negative correlation between C-reactive protein and serum cortisol levels was revealed ( rho = –0.40, n = 14). C-reactive protein in those patients was not correlated with Montgomery-Åsberg Depression Rating Scale scores. We observed a significant reduction of C-reactive protein levels across time in both patients and controls treated with ayahuasca, but not with placebo. Patients treated with ayahuasca showed a significant correlation ( rho = + 0.57) between larger reductions of C-reactive protein and lower depressive symptoms at 48 hours after substance ingestion (Montgomery-Åsberg Depression Rating Scale). No significant result with respect to interleukin 6 and brain-derived neurotrophic factor was found. Furthermore, these biomarkers did not predict the antidepressant response or remission rates observed. Conclusions: These findings enhance the understanding of the biological mechanisms behind the observed antidepressant effects of ayahuasca and encourage further clinical trials in adults with depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Evidence from four randomized, placebo-controlled studies investigating the acute and subacute, but not long-term effects, of a single dose of psychedelics on a molecular level show that a single treatment with ayahuasca or LSD can, but does not always, increase circulating BDNF in healthy volunteers and TRD patients (47–50) (Table 2).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [48]
In the citing paper
“Conversely, in a follow-up study, a single oral dose of ayahuasca (1 mL/kg, p.o., 0.36 mg/mL DMT, 1.86 mg/mL harmine, 0.24 mg/mL harmaline) administered to TRD patients (n = 28) and healthy controls (n = 45) in a controlled setting did not affect serum BDNF levels at 48 h after administration (48).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [48]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“Depression severity was assessed by the Hamilton Depression Scale (score >17) (Hamilton, 1960) and the Montgomery-Åsberg Depression Rating Scale (MADRS; score >18) (Montgomery and Åsberg, 1979).”
MethodA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 1×
“Depression severity was assessed by the Hamilton Depression Scale (score >17) (Hamilton, 1960) and the Montgomery-Åsberg Depression Rating Scale (MADRS; score >18) (Montgomery and Åsberg, 1979).”
MethodInflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848 · cited 2×
“We also considered possible correlations between inflammatory, BDNF, and cortisol responses to treatment, as interaction between them has been described (Gałecki and Talarowska, 2018; Miller et al., 2009) and taking into account that ayahuasca increased BDNF levels at D2 in volunteers of this trial (Almeida et al.”
BackgroundMethodThe pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · cited 3×
“, 2016); and (c) the activation of the IL-6 trans-signaling pathway reduces IL-6 levels in the blood (Scheller et al., 2011).”
BackgroundSlavich, G. M., & Irwin, M. R. (2014) · Psychological Bulletin · doi:10.1037/a0035302 · Cited by 2,206 · cited 15×
“Pharmacological interventions are the most used therapeutic strategy to treat major depressive disorder (MDD).”
BackgroundInfluentialGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“…interest in the use of classic serotonergic psychedelics for treatment of MDD (ayahuasca: Almeida et al., 2019; Galvão et al., 2018; Osório et al., 2015; Palhano-Fontes et al., 2015, 2018; Sanches et al., 2016; psilocybin: Carhart-Harris et al., 2016; Griffiths et al., 2016; Ross et al., 2016).”
BackgroundObesity and inflammation: the linking mechanism and the complications
Ellulu, M. S., Patimah, I., Khaza’ai, H., Rahmat, A., & Abed, Y. (2017) · Archives of Medical Science · doi:10.5114/aoms.2016.58928 · Cited by 1,982 · cited 1×
“Body mass index (BMI) was used as a co-variable in multivariable analyses due to comorbid between treatmentresistant depression and obesity, which has been associated with inflammation (Ellulu et al., 2017; Jantaratnotai et al., 2017).”
MethodRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698 · cited 14×
“, 2018), there is a renewal interest in the use of classic serotonergic psychedelics for treatment of MDD (ayahuasca: Almeida et al., 2019; Galvão et al., 2018; Osório et al., 2015; Palhano-Fontes et al., 2015, 2018; Sanches et al., 2016; psilocybin: Carhart-Harris et al., 2016; Griffiths et al., 2016; Ross et al., 20…”
BackgroundInfluentialRaison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · cited 2×
“The pre-treatment CRP levels observed here in patients were characterized as a low-grade inflammatory profile (CRP level >3 mg/L; healthy adult population <1 mg /L) (Macy et al., 1997; Osimo et al., 2019; Raison et al., 2013; Shine et al., 1981).”
BackgroundCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 1×
“…interest in the use of classic serotonergic psychedelics for treatment of MDD (ayahuasca: Almeida et al., 2019; Galvão et al., 2018; Osório et al., 2015; Palhano-Fontes et al., 2015, 2018; Sanches et al., 2016; psilocybin: Carhart-Harris et al., 2016; Griffiths et al., 2016; Ross et al., 2016).”
BackgroundFirth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531 · cited 1×
“Therefore, our findings support the use of ayahuasca as an alternative treatment with anti-inflammatory effects for MDD (Firth et al., 2019; Sarris et al., 2018) and reinforce the utility of biomarkers in depression (Miller and O’Callaghan, 2013).”
ResultSelf-citationAssociations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
Harris, T. B., Ferrucci, L., Tracy, R. P., Corti, M. C., Wacholder, S., Ettinger, W. H., Heimovitz, H., Cohen, H. J., & Wallace, R. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00066-2 · Cited by 1,488 · cited 2×
“, 2018), have shown increases in CRP independently of IL-6 (Harris et al., 1999; Shibasaki et al., 2016).”
BackgroundHaapakoski, R., Mathieu, J., Ebmeier, K. P., Alenius, H., & Kivimäki, M. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.06.001 · Cited by 1,129 · cited 3×
“Therefore, some studies have identified an association between inflammation and depression severity (Haapakoski et al., 2015).”
BackgroundResultSequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852 · cited 7×
“In this trial patients received a single dose of ayahuasca or placebo and a significant antidepressant effect of ayahuasca was observed 1, 2, and 7 days after treatment (Palhano-Fontes et al., 2018).”
BackgroundMethodInfluentialSelf-citationMacy, E. M., Hayes, T. E., & Tracy, R. P. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.1.52 · Cited by 797 · cited 1×
“The pre-treatment CRP levels observed here in patients were characterized as a low-grade inflammatory profile (CRP level >3 mg/L; healthy adult population <1 mg /L) (Macy et al., 1997; Osimo et al., 2019; Raison et al., 2013; Shine et al., 1981).”
BackgroundOsimo, E. F., Baxter, L. J., Lewis, G., Jones, P. B., & Khandaker, G. M. (2019) · Psychological Medicine · doi:10.1017/s0033291719001454 · Cited by 774 · cited 2×
“The pre-treatment CRP levels observed here in patients were characterized as a low-grade inflammatory profile (CRP level >3 mg/L; healthy adult population <1 mg /L) (Macy et al., 1997; Osimo et al., 2019; Raison et al., 2013; Shine et al., 1981).”
BackgroundInterleukin-6 and its receptors: a highly regulated and dynamic system
Wolf, J., Rose-John, S., & Garbers, C. (2014) · Cytokine · doi:10.1016/j.cyto.2014.05.024 · Cited by 618 · cited 1×
“Therefore, to distinguish if the IL-6 change is a pro-inflammatory or anti-inflammatory response, it is necessary to explore downstream molecules, such as its receptors (Wolf et al., 2014).”
BackgroundIs depression an inflammatory disorder?
Raison, C. L., & Miller, A. H. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0232-0 · Cited by 524 · cited 1×
“The inflammation observed in a subset of depressive patients, such as treatment-resistant patients, is lower than that seen in typical inflammatory diseases, such as infections or autoimmune disorders (Chamberlain et al., 2019; Osimo et al., 2019; Raison and Miller, 2011).”
BackgroundOsório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488 · cited 15×
“, 2018), there is a renewal interest in the use of classic serotonergic psychedelics for treatment of MDD (ayahuasca: Almeida et al., 2019; Galvão et al., 2018; Osório et al., 2015; Palhano-Fontes et al., 2015, 2018; Sanches et al., 2016; psilocybin: Carhart-Harris et al., 2016; Griffiths et al., 2016; Ross et al., 20…”
BackgroundMethodInfluentialSelf-citationSanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466 · cited 15×
“, 2018), there is a renewal interest in the use of classic serotonergic psychedelics for treatment of MDD (ayahuasca: Almeida et al., 2019; Galvão et al., 2018; Osório et al., 2015; Palhano-Fontes et al., 2015, 2018; Sanches et al., 2016; psilocybin: Carhart-Harris et al., 2016; Griffiths et al., 2016; Ross et al., 20…”
BackgroundMethodInfluentialSelf-citationInterleukin-6: A Masterplayer in the Cytokine Network
Uciechowski, P., & Dempke, W. C. M. (2020) · Oncology · doi:10.1159/000505099 · Cited by 465 · cited 2×
“IL-6 is a specific inflammatory biomarker produced by immune and non-immune cells that has pleiotropic actions on the immune system, physiology processes, and behavior (Uciechowski and Dempke, 2020).”
BackgroundPalhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454 · cited 1×
“…interest in the use of classic serotonergic psychedelics for treatment of MDD (ayahuasca: Almeida et al., 2019; Galvão et al., 2018; Osório et al., 2015; Palhano-Fontes et al., 2015, 2018; Sanches et al., 2016; psilocybin: Carhart-Harris et al., 2016; Griffiths et al., 2016; Ross et al., 2016).”
BackgroundSelf-citationKöhler, C. A., Freitas, T. H., Stubbs, B., Maes, M., Solmi, M., Veronese, N., de Andrade, N. Q., Morris, G., Fernandes, B. S., Brunoni, A. R., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0632-1 · Cited by 449 · cited 1×
“, 2018), possibly due to the heterogeneous study design (Arteaga-Henríquez et al., 2019; Horn et al., 2018; Köhler et al., 2018) and IL-6 complex physiological mechanisms (Uciechowski and Dempke, 2020).”
BackgroundLiu, J. J., Wei, Y. B., Strawbridge, R., Bao, Y., Chang, S., Shi, L., Que, J., Gadad, B. S., Trivedi, M. H., Kelsoe, J. R., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0474-5 · Cited by 429 · cited 1×
“However, other publications have reported no correlations between inflammation and remission (Bot et al., 2011; Liu et al., 2019).”
BackgroundInflammation and depression: a causal or coincidental link to the pathophysiology?
Leonard, B. E. (2018) · Acta Neuropsychiatrica · doi:10.1017/neu.2016.69 · Cited by 409 · cited 1×
“A similar relation between inflammation and cortisol was observed in depressive patients (Cubała and Landowski, 2014; Leonard, 2018).”
BackgroundTreatment-resistant depression and peripheral C-reactive protein.
Chamberlain, S. R., Cavanagh, J., de Boer, P., Mondelli, V., Jones, D. N. C., Drevets, W. C., Cowen, P. J., Harrison, N. A., Pointon, L., Pariante, C. M., et al. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2018.66 · Cited by 400 · cited 1×
“The inflammation observed in a subset of depressive patients, such as treatment-resistant patients, is lower than that seen in typical inflammatory diseases, such as infections or autoimmune disorders (Chamberlain et al., 2019; Osimo et al., 2019; Raison and Miller, 2011).”
BackgroundJesulola, E., Micalos, P., & Baguley, I. J. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.12.025 · Cited by 379 · cited 4×
“These biological alterations show multiple physiological interactions and have been associated with MDD (Dooley et al., 2018; Jesulola et al., 2018).”
BackgroundInfluentialSolid phase radioimmunoassays for human C-reactive protein
Shine, B., de Beer, F. C., & Pepys, M. B. (1981) · Clinica Chimica Acta · doi:10.1016/0009-8981(81)90005-x · Cited by 319 · cited 1×
“The pre-treatment CRP levels observed here in patients were characterized as a low-grade inflammatory profile (CRP level >3 mg/L; healthy adult population <1 mg /L) (Macy et al., 1997; Osimo et al., 2019; Raison et al., 2013; Shine et al., 1981).”
BackgroundThe hallucinogenic world of tryptamines: an updated review
Araújo, A. M., Carvalho, F., Bastos, M. D. L., Guedes de Pinho, P., & Carvalho, M. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1513-x · Cited by 292 · cited 2×
“In total, 73 volunteers participated in the trial; all were adults and naïve to any classic serotonergic psychedelic that is an agonist of 5-HT2A, such as ayahuasca, psilocybin, mescaline, and LSD (Araújo et al., 2015).”
BackgroundHaroon, E., Daguanno, A. W., Woolwine, B. J., Goldsmith, D. R., Baer, W. M., Wommack, E. C., Felger, J. C., & Miller, A. H. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.05.026 · Cited by 291 · cited 2×
“…some studies have shown an association between the presence of low-grade inflammatory profiles and treatment resistance in depressive patients (Haroon et al., 2018; Raison et al., 2013), these results point to a relevant role of ayahuasca, which shows concomitant antidepressant and…”
ResultThe interface of depression and obesity
Jantaratnotai, N., Mosikanon, K., Lee, Y., & McIntyre, R. S. (2017) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2016.07.003 · Cited by 282 · cited 1×
“Body mass index (BMI) was used as a co-variable in multivariable analyses due to comorbid between treatmentresistant depression and obesity, which has been associated with inflammation (Ellulu et al., 2017; Jantaratnotai et al., 2017).”
MethodPsychedelics as anti-inflammatory agents
Flanagan, T. W., & Nichols, C. D. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1481827 · Cited by 267 · cited 1×
“Some studies have also proposed a direct anti-inflammatory effect of psychedelics via serotonin 2A receptors (5-HT2A) and sigma-1 receptor (σ1R) (Flanagan and Nichols, 2018; Szabo et al., 2014).”
BackgroundConway, C. R., George, M. S., & Sackeim, H. A. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.2586 · Cited by 244 · cited 2×
“not achieving remission after being treated) to at least two antidepressant medications from different classes (Conway et al., 2017).”
MethodSeeing with the eyes shut: neural basis of enhanced imagery following ayahuasca ingestion.
de Araujo, D. B., Ribeiro, S., Cecchi, G. A., Carvalho, F. M., Sanchez, T. A., Pinto, J. P., de Martinis, B. S., Crippa, J. A., Hallak, J. E. C., & Santos, A. C. (2012) · Human Brain Mapping · doi:10.1002/hbm.21381 · Cited by 239
Effect of antidepressant treatment on peripheral inflammation markers – A meta-analysis
Więdłocha, M., Marcinowicz, P., Krupa, R., Janoska-Jaździk, M., Janus, M., Dębowska, W., Mosiołek, A., Waszkiewicz, N., & Szulc, A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.026 · Cited by 233 · cited 7×
“Although traditionally IL-6 and CRP are physiologically linked, some studies, including in depressive patients (Więdłocha et al., 2018), have shown increases in CRP independently of IL-6 (Harris et al., 1999; Shibasaki et al., 2016).”
BackgroundInfluentialRecurrence in major depression: A conceptual analysis
Monroe, S. M., & Harkness, K. L. (2011) · Psychological Review · doi:10.1037/a0025190 · Cited by 225 · cited 13×
“Pharmacological interventions are the most used therapeutic strategy to treat major depressive disorder (MDD).”
BackgroundInfluentialZou, W., Feng, R., & Yang, Y. (2018) · PLOS ONE · doi:10.1371/journal.pone.0197267 · Cited by 224 · cited 15×
“Pharmacological interventions are the most used therapeutic strategy to treat major depressive disorder (MDD).”
BackgroundResultInfluentialArteaga-Henríquez, G., Simon, M. S., Burger, B., Weidinger, E., Wijkhuijs, A., Arolt, V., Birkenhager, T. K., Musil, R., Müller, N., & Drexhage, H. A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00458 · Cited by 215 · cited 4×
“A reduction in IL-6 after treatment has been observed, but not in CRP and TNF-α (Więdłocha et al., 2018), although these findings are not in consensus (Arteaga-Henríquez et al., 2019).”
BackgroundInfluentialInflammatory theory of depression
Gałecki, P., & Talarowska, M. (2018) · Psychiatria Polska · doi:10.12740/pp/76863 · Cited by 192 · cited 2×
“We also considered possible correlations between inflammatory, BDNF, and cortisol responses to treatment, as interaction between them has been described (Gałecki and Talarowska, 2018; Miller et al., 2009) and taking into account that ayahuasca increased BDNF levels at D2 in volunteers of this trial (Almeida et al.”
MethodSzabo, A., Kovacs, A., Frecska, E., & Rajnavolgyi, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106533 · Cited by 191 · cited 2×
“Some studies have also proposed a direct anti-inflammatory effect of psychedelics via serotonin 2A receptors (5-HT2A) and sigma-1 receptor (σ1R) (Flanagan and Nichols, 2018; Szabo et al., 2014).”
BackgroundBDNF isoforms: a round trip ticket between neurogenesis and serotonin?
Foltran, R. B., & Diaz, S. L. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13658 · Cited by 187 · cited 1×
“The reduced level of BDNF is suggested to be associated with changes in brain volume in specific areas among patients with MDD, such as hippocampus (Foltran and Diaz, 2016; Jesulola et al., 2018).”
Identifying fast-onset antidepressants using rodent models
Ramaker, M. J., & Dulawa, S. C. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.36 · Cited by 182 · cited 1×
“These substances have been identified as potential fast-acting antidepressants, due to their short latency for clinical improvement (Almeida et al., 2019; Ramaker and Dulawa, 2017).”
BackgroundAlmeida, R. N. D., Galvão, A. C. D. M., da Silva, F. S., Silva, E. A. D. S., Palhano-Fontes, F., Maia-de-Oliveira, J. P., de Araújo, L.-S. B., Lobão-Soares, B., & Galvão-Coelho, N. L. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.01234 · Cited by 177 · cited 7×
“We also explored the correlation between inflammatory biomarkers, cortisol and BDNF serum levels, which were previously evaluated from this clinical trial (Almeida et al., 2019; Galvão et al., 2018), and we expect to find negative relationship between them.”
BackgroundMethodInfluentialSelf-citationDooley, L. N., Kuhlman, K. R., Robles, T. F., Eisenberger, N. I., Craske, M. G., & Bower, J. E. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.09.006 · Cited by 176 · cited 2×
“These biological alterations show multiple physiological interactions and have been associated with MDD (Dooley et al., 2018; Jesulola et al., 2018).”
BackgroundSchmit, X., & Vincent, J. L. (2008) · Infection · doi:10.1007/s15010-007-7077-9 · Cited by 165 · cited 2×
“, 2005); (b) IL-6 increases are not simultaneous to CRP, but precede CRP by 1–2 days (Schmit and Vincent, 2008; Shibasaki et al., 2016); and (c) the activation of the IL-6 trans-signaling pathway reduces IL-6 levels in the blood (Scheller et al.”
BackgroundChen, M.-H., Li, C.-T., Lin, W.-C., Hong, C.-J., Tu, P.-C., Bai, Y.-M., Cheng, C.-M., & Su, T.-P. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.08.078 · Cited by 159 · cited 1×
“Anti-inflammatory properties have also been proposed for ketamine, an anesthetic with psychedelic and antidepressant actions; however, such effects remain controversial (Chen et al., 2018; Park et al., 2017).”
BackgroundAntidepressant therapy and C-reactive protein levels
O'Brien, S. M., Scott, L. V., & Dinan, T. G. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.011015 · Cited by 148 · cited 1×
“Other studies with depressive patients have also reported significant decreases in CRP levels after treatment (O’Brien et al., 2006); however, differences exist between classes of antidepressants (ArteagaHenríquez et al.”
BackgroundInflammatory profiles of severe treatment-resistant depression
Strawbridge, R., Hodsoll, J., Powell, T. R., Hotopf, M., Hatch, S. L., Breen, G., & Cleare, A. J. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.12.037 · Cited by 134
Horn, S. R., Long, M. M., Nelson, B. W., Allen, N. B., Fisher, P. A., & Byrne, M. L. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.06.016 · Cited by 129 · cited 2×
“, 2018), possibly due to the heterogeneous study design (Arteaga-Henríquez et al., 2019; Horn et al., 2018; Köhler et al., 2018) and IL-6 complex physiological mechanisms (Uciechowski and Dempke, 2020).”
BackgroundKramer, F., Torzewski, J., Kamenz, J., Veit, K., Hombach, V., Dedio, J., & Ivashchenko, Y. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2007.12.017 · Cited by 127 · cited 2×
“However, the mechanisms behind such changes are not completely understood, some hypotheses have been raised: (a) other inflammatory factors than IL-6, such as IL-1β, could stimulate CRP synthesis and release it from the liver (Ivashchenko et al., 2005); (b) IL-6 increases are not simultaneous to CRP, but precede CRP b…”
BackgroundVerduijn, J., Milaneschi, Y., Schoevers, R. A., van Hemert, A. M., Beekman, A. T. F., & Penninx, B. W. J. H. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.137 · Cited by 114 · cited 3×
“Similar findings have been identified the CRP, as a non-specific etiological factor for MDD (Verduijn et al., 2015; Zou et al., 2018).”
BackgroundResultGalvão, A. C. D. M., de Almeida, R. N., Silva, E. A. D. S., Freire, F. A. M., Palhano-Fontes, F., Onias, H., Arcoverde, E., Maia-de-Oliveira, J. P., de Araújo, D. B., Lobão-Soares, B., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00185 · Cited by 108 · cited 18×
“However, this correlation at baseline was not observed in the control group, probably because they presented eucortisolemia (Galvão et al., 2018).”
BackgroundMethodInfluentialSelf-citationBlood biomarkers and treatment response in major depression
Mora, C., Zonca, V., Riva, M. A., & Cattaneo, A. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1470927 · Cited by 107
Park, M., Newman, L. E., Gold, P. W., Luckenbaugh, D. A., Yuan, P., Machado-Vieira, R., & Zarate, C. A. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.09.025 · Cited by 93 · cited 1×
“Anti-inflammatory properties have also been proposed for ketamine, an anesthetic with psychedelic and antidepressant actions; however, such effects remain controversial (Chen et al., 2018; Park et al., 2017).”
BackgroundHengartner, M. P., & Plöderl, M. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00517 · Cited by 93
Harmine is an inflammatory inhibitor through the suppression of NF-κB signaling
Liu, X., Li, M., Tan, S., Wang, C., Fan, S., & Huang, C. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.126 · Cited by 92 · cited 1×
“Harmine, present in ayahuasca, also shows anti-inflammatory activity by suppression of nuclear factor-κB signaling (Xin et al., 2017).”
BackgroundCarboni, L., McCarthy, D. J., Delafont, B., Filosi, M., Ivanchenko, E., Ratti, E., Learned, S. M., Alexander, R., & Domenici, E. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0521-7 · Cited by 89 · cited 1×
“In fact, different correlations (positive, negative, or non-significant) are seen between inflammation and clinical characteristics of depression (Carboni et al., 2019).”
BackgroundDoes escitalopram reduce neurotoxicity in major depression?
Halaris, A., Myint, A.-M., Savant, V., Meresh, E., Lim, E., Guillemin, G., Hoppensteadt, D., Fareed, J., & Sinacore, J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.04.026 · Cited by 86 · cited 2×
“The literature reports conflicting responses of IL-6 after treatment with antidepressants (Halaris et al., 2015; Więdłocha et al., 2018), possibly due to the heterogeneous study design (Arteaga-Henríquez et al., 2019; Horn et al., 2018; Köhler et al., 2018) and IL-6 complex physiological mechanisms…”
BackgroundJha, M., & Trivedi, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010233 · Cited by 86 · cited 1×
“MDD is a heterogeneous disorder and the understanding of its neurobiology is essential for the development of more efficient treatments (Jha and Trivedi, 2018; Mora et al., 2018).”
BackgroundCircadian Rhythms in Plasma Brain-derived Neurotrophic Factor Differ in Men and Women
Cain, S. W., Chang, A., Vlasac, I., Tare, A., Anderson, C., Czeisler, C. A., & Saxena, R. (2017) · Journal of Biological Rhythms · doi:10.1177/0748730417693124 · Cited by 68 · cited 2×
“these biomarkers are modulated by multiple routes and they show circadian oscillation (Cain et al., 2017; Slavich and Irwin, 2014), then, a single blood collection may not be enough to show them.”
BackgroundSequenced Treatment Alternatives to Relieve Depression (STAR*D): Part 1: Study Design
Howland, R. H. (2008) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20080901-06 · Cited by 59 · cited 1×
“This instrument was selected because it can assess changes in depressive symptoms in short intervals (less than 7 days) and is widely used in clinical trials for depression (Howland, 2008; Rush et al., 2004).”
Cubała, W. J., & Landowski, J. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.004 · Cited by 49 · cited 2×
“Drug-naïve depressive patients have showed similar levels of CRP or IL-6 to healthy controls (Cubała and Landowski, 2014; Zou et al., 2018).”
BackgroundPersonalized medicine in major depressive disorder — Opportunities and pitfalls
Miller, D. B., & O'Callaghan, J. P. (2012) · Metabolism · doi:10.1016/j.metabol.2012.08.021 · Cited by 45 · cited 2×
“, 2018) and reinforce the utility of biomarkers in depression (Miller and O’Callaghan, 2013).”
BackgroundResultBot, M., Carney, R. M., Freedland, K. E., Rubin, E. H., Rich, M. W., Steinmeyer, B. C., & Mann, D. L. (2011) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2010.11.006 · Cited by 41 · cited 1×
“However, other publications have reported no correlations between inflammation and remission (Bot et al., 2011; Liu et al., 2019).”
BackgroundKnol, M., Groenwold, R., & Grobbee, D. (2012) · European Journal of Preventive Cardiology · doi:10.1177/1741826711421688 · Cited by 41 · cited 2×
“The reported trial was conducted in accordance with the consolidated standards of reporting trials statement (Supplementary Figure S1), according to which significance tests for eventual baseline differences of depression scores should not be reported (Knol et al., 2012).”
BackgroundMethodIvashchenko, Y., Kramer, F., Schäfer, S., Bucher, A., Veit, K., Hombach, V., Busch, A., Ritzeler, O., Dedio, J., & Torzewski, J. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000150041.81963.68 · Cited by 35 · cited 2×
“However, the mechanisms behind such changes are not completely understood, some hypotheses have been raised: (a) other inflammatory factors than IL-6, such as IL-1β, could stimulate CRP synthesis and release it from the liver (Ivashchenko et al., 2005); (b) IL-6 increases are not simultaneous to CRP, but precede CRP b…”
BackgroundZhang, J., Yue, Y., Thapa, A., Fang, J., Zhao, S., Shi, W., Yang, Z., Li, Y., & Yuan, Y. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.03.001 · Cited by 35 · cited 1×
“In fact, the anti-inflammatory effects of antidepressants may be influenced by the pre-treatment level of inflammation (Arteaga-Henríquez, et al., 2019; Zhang et al., 2019).”
BackgroundAngoa‐Pérez, M., Anneken, J. H., & Kuhn, D. M. (2017) · Journal of Psychiatry and Psychiatric Disorders · doi:10.26502/jppd.2572-519x0025 · Cited by 31
Shibasaki, J., Shimokaze, T., Kishigami, M., Ohyama, M., Hoshino, R., Toyoshima, K., Itani, Y., & Saito, J. (2016) · American Journal of Perinatology · doi:10.1055/s-0036-1583192 · Cited by 24 · cited 4×
“, 2005); (b) IL-6 increases are not simultaneous to CRP, but precede CRP by 1–2 days (Schmit and Vincent, 2008; Shibasaki et al., 2016); and (c) the activation of the IL-6 trans-signaling pathway reduces IL-6 levels in the blood (Scheller et al.”
BackgroundInfluentialEvidence for the treatment of moderate depression: a systematic review
Aherne, D., Fitzgerald, A., Aherne, C., Fitzgerald, N., Slattery, M., & Whelan, N. (2017) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2017.10 · Cited by 10 · cited 2×
“However, about 50% of treatments are unsuccessful in preventing relapse, leading to recurrent MDD (Aherne et al., 2017; Monroe and Harkness, 2011).”
Background
Research works printed but not linked: 4
- Gowda S, 2009, Pan Afr Med J, 3, 17
- Köhler CA, 2018, Mol Neurobiol, 55, 4195
- Sarris J, 2018, Am J Psychiatry, 73, 575
- Sousa MBC, 2015, Psychol Stud, 20, 1
Cited by
de Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.724606 · Cited by 269
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Galvão-Coelho, N. L., Marx, W., Gonzalez, M., Sinclair, J., de Manincor, M., Perkins, D., & Sarris, J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05719-1 · Cited by 137
Self-citationInflammatory signaling mechanisms in bipolar disorder
Jones, G. H., Vecera, C. M., Pinjari, O. F., & Machado‐Vieira, R. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00742-6 · Cited by 160
Kadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa087 · Cited by 99
Metadata
- Authors
- Galvão-Coelho, N. L., de Menezes Galvão, A. C., de Almeida, R. N., Palhano-Fontes, F., Campos Braga, I., Lobão Soares, B., Maia-de-Oliveira, J. P., Perkins, D., Sarris, J., & de Araujo, D. B.
- Affiliations
- Department of Physiology and Behavior, Laboratory of Hormone Measurement, Federal University of Rio Grande do Norte, Natal, Brazil
- Universidade Federal do Rio Grande do Norte (BR)
- Brain Institute, Federal University of Rio Grande do Norte, Natal, Brazil
- National Science and Technology Institute for Translational Medicine, Natal, Brazil
- The University of Melbourne (AU)
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2020-07-10
- Volume
- 34
- Issue
- 10
- Pages
- 1125-1133
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W3023636576
- Semantic Scholar
- 26ddc50420d68a18d4f5853e948427e21b4025ad
- Cited by
- 128
- References
- 71
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 22 · 2023: 31 · 2022: 23 · 2021: 20 · 2020: 6
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (1577/2013, 1677/2012)
- National Science and Technology Institute for Translational Medicine (Fapesp 2014/50891-1 CNPq 465458/2014-9).)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (466760/2014, 479466/2013)
- instituto nacional de ciência e tecnologia translacional em medicina
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ayahuasca, antidepressant effects, treatment-resistant depression, inflammatory markers, C-reactive protein, interleukin-6, brain-derived neurotrophic factor, serum cortisol, neuroinflammation, antidepressant response prediction
- MeSH terms
- Adult, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Female, Humans, Inflammation, Male, Psychiatric Status Rating Scales, Biomarkers, Case-Control Studies, Treatment Outcome, Plant Preparations, Banisteriopsis, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.